Fueled by surging demand for blockbuster weight-loss drugs Mounjaro and Zepbound, Eli Lilly briefly crossed the $1 trillion mark, cementing its lead in the booming obesity-treatment market and outpacing every other pharmaceutical rival| Read More ynet – Business